Electrocortical changes associated with minocycline treatment in fragile X syndrome
Open accessAbstract
Minocycline normalizes synaptic connections and behavior in the knockout mouse model of fragile X syndrome (FXS). Human-targeted treatment trials with minocycline have shown benefits in behavioral measures and parent reports. Event-related potentials (ERPs) may provide a sensitive method of monitoring treatment response and changes in coordinated brain activity. Measurement of electrocortical changes due to minocycline was done in a double-blind, placebo-controlled crossover treatment trial in children with FXS. Children with FXS (Mean age 10.5 years) were randomized to minocycline or placebo treatment for 3 months then changed to the other treatment for 3 months. The minocycline dosage ranged from 25–100 mg daily, based on weight. Twelve individuals with FXS (eight male, four female) completed ERP studies using a passive auditory oddball paradigm. Current source density (CSD) and ERP analysis at baseline showed high-amplitude, long-latency components over temporal regions. After 3 months of treatment with minocycline, the temporal N1 and P2 amplitudes were significantly reduced compared with placebo. There was a significant amplitude increase of the central P2 component on minocycline. Electrocortical habituation to auditory stimuli improved with minocycline treatment. Our study demonstrated improvements of the ERP in children with FXS treated with minocycline, and the potential feasibility and sensitivity of ERPs as a cognitive biomarker in FXS treatment trials.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Auditory event-related potential habituation deficits in humans with Fragile X Syndrome are reversed by minocycline treatment.
“The ERP habituation deficits in humans with FXS are reversed by minocycline treatment but the underlying mechanisms are not known (Schneider et al. 2013).”
From Matrix metalloproteinase-9 deletion rescues auditory evoked potential habituation deficit in a mouse model of Fragile X Syndrome (2016) · cites this paper as Schneider et al. 2013
Reduced N1 habituation in Fmr1 KO mice resembles human FXS observations, providing an analogous functional sensory outcome measure in mice and humans (Castren et al., 2003; Van der Molen et al., 2012; Schneider et al., 2013).
“The reduced habituation of N1 amplitude in Fmr1 KO mice is similar to observations in humans with FXS providing, for the first time, an analogous functional sensory outcome measure in mice and humans (Castren et al., 2003; Van der Molen et al., 2012; Schneider et al., 2013).”
From Matrix metalloproteinase-9 deletion rescues auditory evoked potential habituation deficit in a mouse model of Fragile X Syndrome (2016) · cites this paper as Schneider et al., 2013
Minocycline, which lowers MMP-9 activity and levels, reduces ERP habituation deficits in humans with FXS (Schneider et al., 2013).
“Treatment with minocycline, which reduces MMP-9 activity and levels, reduces ERP habituation deficits humans with FXS (Schneider et al., 2013).”
From Matrix metalloproteinase-9 deletion rescues auditory evoked potential habituation deficit in a mouse model of Fragile X Syndrome (2016) · cites this paper as Schneider et al., 2013
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
(1976) · Medical Entomology and Zoology · Cited by 8,899 · see citing works
Spherical splines for scalp potential and current density mapping
Perrin, F., Pernier, J., Bertrand, O., & Echallier, J. F. (1989) · Electroencephalography and Clinical Neurophysiology · doi:10.1016/0013-4694(89)90180-6 · Cited by 2,706 · see citing works
Picton, T. W., Bentin, S., Berg, P., Donchin, E., Hillyard, S. A., Johnson, R., Miller, G. A., Ritter, W., Ruchkin, D. S., Rugg, M. D., et al. (2000) · Psychophysiology · doi:10.1111/1469-8986.3720127 · Cited by 2,157 · see citing works
The mGluR theory of fragile X mental retardation
Bear, M. F., Huber, K. M., & Warren, S. T. (2004) · Trends in Neurosciences · doi:10.1016/j.tins.2004.04.009 · Cited by 1,580 · see citing works
Duncan, C. C., Barry, R. J., Connolly, J. F., Fischer, C., Michie, P. T., Näätänen, R., Polich, J., Reinvang, I., & Van Petten, C. (2009) · Clinical Neurophysiology · doi:10.1016/j.clinph.2009.07.045 · Cited by 1,191 · see citing works
DNA methylation represses <i>FMR-1</i> transcription in fragile X syndrome
Sutcliffe, J. S., Nelson, D. L., Zhang, F., Pieretti, M., Caskey, C. T., Saxe, D., & Warren, S. T. (1992) · Human Molecular Genetics · doi:10.1093/hmg/1.6.397 · Cited by 680 · see citing works
Jacquemont, S., Curie, A., des Portes, V., Torrioli, M. G., Berry-Kravis, E., Hagerman, R. J., Ramos, F. J., Cornish, K., He, Y., Paulding, C., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3001708 · Cited by 609 · see citing works
Self-citationBilousova, T. V., Dansie, L., Ngo, M., Aye, J., Charles, J. R., Ethell, D. W., & Ethell, I. M. (2009) · Journal of Medical Genetics · doi:10.1136/jmg.2008.061796 · Cited by 465 · see citing works
Näätänen, R., Kujala, T., Escera, C., Baldeweg, T., Kreegipuu, K., Carlson, S., & Ponton, C. W. (2011) · Clinical Neurophysiology · doi:10.1016/j.clinph.2011.09.020 · Cited by 426 · see citing works
Audiogenic Seizures Susceptibility in Transgenic Mice with Fragile X Syndrome
Musumeci, S. A., Bosco, P., Calabrese, G., Bakker, C., De Sarro, G. B., Elia, M., Ferri, R., & Oostra, B. A. (2000) · Epilepsia · doi:10.1111/j.1528-1157.2000.tb01499.x · Cited by 289 · see citing works
Epilepsy in fragile X syndrome
Berry‐Kravis, E. (2002) · Developmental Medicine & Child Neurology · doi:10.1111/j.1469-8749.2002.tb00277.x · Cited by 271 · see citing works
Tenke, C. E., & Jürgen Kayser, A. (2012) · Clinical Neurophysiology · doi:10.1016/j.clinph.2012.06.005 · Cited by 270 · see citing works
Epilepsy and EEG Findings in Males with Fragile X Syndrome
Musumeci, S. A., Hagerman, R. J., Ferri, R., Bosco, P., Bernardina, B. D., Tassinari, C. A., Sarro, G. D., & Elia, M. (1999) · Epilepsia · doi:10.1111/j.1528-1157.1999.tb00824.x · Cited by 250 · see citing works
Self-citationOpen-label add-on treatment trial of minocycline in fragile X syndrome.
Paribello, C., Tao, L., Folino, A., Berry-Kravis, E., Tranfaglia, M., Ethell, I. M., & Ethell, D. W. (2010) · BMC Neurology · doi:10.1186/1471-2377-10-91 · Cited by 223 · see citing works
Chuang, S.-C., Zhao, W., Bauchwitz, R., Yan, Q., Bianchi, R., & Wong, R. K. S. (2005) · Journal of Neuroscience · doi:10.1523/jneurosci.1777-05.2005 · Cited by 190 · see citing works
The GABAA receptor: a novel target for treatment of fragile X?
D’Hulst, C., & Kooy, R. F. (2007) · Trends in Neurosciences · doi:10.1016/j.tins.2007.06.003 · Cited by 166 · see citing works
Augmentation of auditory N1 in children with fragile X syndrome.
Castrén, M., Pääkkönen, A., Tarkka, I. M., Ryynänen, M., & Partanen, J. (2003) · Brain Topography · doi:10.1023/a:1022606200636 · Cited by 123 · see citing works
BC1 Regulation of Metabotropic Glutamate Receptor-Mediated Neuronal Excitability
Zhong, J. W., Chuang, S.-C., Bianchi, R., Zhao, W., Lee, H., Fenton, A. A., Wong, R. K. S., & Tiedge, H. (2009) · Journal of Neuroscience · doi:10.1523/jneurosci.3893-08.2009 · Cited by 119 · see citing works
Utari, A., Chonchaiya, W., Rivera, S. M., Schneider, A., Hagerman, R. J., Faradz, S. M. H., Ethell, I. M., & Nguyen, D. V. (2010) · American Journal on Intellectual and Developmental Disabilities · doi:10.1352/1944-7558-115.5.433 · Cited by 105 · see citing works
Self-citationAuditory change detection in fragile X syndrome males: A brain potential study
van der Molen, M. J. W., van der Molen, M. W., Ridderinkhof, K. R., Hamel, B. C. J., Curfs, L., & Ramakers, G. J. A. (2011) · Clinical Neurophysiology · doi:10.1016/j.clinph.2011.11.039 · Cited by 90 · see citing works
Van der Molen, M. J. W., Van der Molen, M. W., Ridderinkhof, K. R., Hamel, B. C. J., Curfs, L. M. G., & Ramakers, G. J. A. (2012) · Clinical Neurophysiology · doi:10.1016/j.clinph.2011.08.023 · Cited by 88 · see citing works
Fragile X syndrome—From genes to cognition
Schneider, A., Hagerman, R. J., & Hessl, D. R. (2009) · Developmental Disabilities Research Reviews · doi:10.1002/ddrr.80 · Cited by 87 · see citing works
Self-citationPrepulse inhibition in fragile X syndrome: Feasibility, reliability, and implications for treatment
Hessl, D. R., Berry‐Kravis, E., Cordeiro, L., Yuhas, J. M., Ornitz, E. M., Campbell, A., Chruscinski, E., Hervey, C. M., Long, J. M., & Hagerman, R. J. (2008) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.30858 · Cited by 77 · see citing works
Self-citationAuditory evoked magnetic fields in adults with fragile X syndrome.
Rojas, D. C., Benkers, T. L., Rogers, S. J., Teale, P. D., Reite, M. L., & Hagerman, R. J. (2001) · Neuroreport · doi:10.1097/00001756-200108080-00056 · Cited by 73 · see citing works
Self-citation1999 Pediatric Academic Societies' Annual Meeting
(1999) · Archives of Pediatrics and Adolescent Medicine · doi:10.1001/archpedi.153.4.418 · Cited by 52 · see citing works
Evoked spikes and giant somatosensory evoked potentials in a patient with fragile-X syndrome
Musumeci, S. A., Elia, M., Ferri, R., Scuderi, C., & Gracco, S. D. (1994) · The Italian Journal of Neurological Sciences · doi:10.1007/bf02339934 · Cited by 19 · see citing works
Attentional set-shifting in fragile X syndrome
van der Molen, M. J. W., van der Molen, M. J. W., Ridderinkhof, K. R., Hamel, B. C. J., Curfs, L., & Ramakers, G. J. A. (2012) · Brain and Cognition · doi:10.1016/j.bandc.2011.12.008 · Cited by 18 · see citing works
Somatosensory evoked potentials and hyplexia outcome
Ferri, R., Gracco, S. D., Elia, M., Musumeci, S. A., & Stefanini, M. (1995) · Neurophysiologie Clinique · doi:10.1016/0987-7053(96)81032-x · Cited by 1 · see citing works
Irwin (2001) · doi:10.1002/1096-8628(20010115)98:2
Flagged first, then by citations
Research works printed but not linked: 1
- Schneider A Leigh MJ Adams P 2012 Differences in Cortical Hyperexcitability in Fragile X Syndrome 13th international fragile X conference Miami, FL, USA
Cited by
Sorted by citations
Hagerman, R. J., Berry-Kravis, E., Hazlett, H. C., Bailey, D. B., Moine, H., Kooy, R. F., Tassone, F., Gantois, I., Sonenberg, N., Mandel, J. L., et al. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.65 · Cited by 838 · see citing works
Self-citationBerry-Kravis, E., Des Portes, V., Hagerman, R., Jacquemont, S., Charles, P., Visootsak, J., Brinkman, M., Rerat, K., Koumaras, B., Zhu, L., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aab4109 · Cited by 270 · see citing works
Self-citationReinhard, S. M., Razak, K., & Ethell, I. M. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00280 · Cited by 219 · see citing works
MMPs in learning and memory and neuropsychiatric disorders
Beroun, A., Mitra, S., Michaluk, P., Pijet, B., Stefaniuk, M., & Kaczmarek, L. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03180-8 · Cited by 207 · see citing works
Sinclair, D., Oranje, B., Razak, K. A., Siegel, S. J., & Schmid, S. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.05.029 · Cited by 198 · see citing works
“Treatment with candidate pharmacotherapy minocycline can decrease N1 and P2 amplitudes in individuals with FXS (Schneider et al., 2013), suggesting that auditory ERP abnormalities can be used as outcome measures in drug treatment in human studies.”
Ethridge, L. E., White, S. P., Mosconi, M. W., Wang, J., Byerly, M. J., & Sweeney, J. A. (2016) · Translational Psychiatry · doi:10.1038/tp.2016.48 · Cited by 188 · see citing works
Fragile X–associated tremor/ataxia syndrome
Hagerman, P. J., & Hagerman, R. J. (2015) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12693 · Cited by 172 · see citing works
Self-citationThe Perineuronal ‘Safety’ Net? Perineuronal Net Abnormalities in Neurological Disorders
Wen, T. H., Binder, D. K., Ethell, I. M., & Razak, K. A. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00270 · Cited by 170 · see citing works
Ethridge, L. E., White, S. P., Mosconi, M. W., Wang, J., Pedapati, E. V., Erickson, C. A., Byerly, M., & Sweeney, J. A. (2017) · Molecular Autism · doi:10.1186/s13229-017-0140-1 · Cited by 164 · see citing works
Updated report on tools to measure outcomes of clinical trials in fragile X syndrome
Budimirovic, D. B., Berry‐Kravis, E., Erickson, C. A., Hall, S. S., Hessl, D. R., Reiss, A. L., King, M. K., Abbeduto, L., & Kaufmann, W. E. (2017) · Journal of Neurodevelopmental Disorders · doi:10.1186/s11689-017-9193-x · Cited by 157 · see citing works
Self-citationSidhu, H., Dansie, L. E., Hickmott, P. W., Ethell, D. W., & Ethell, I. M. (2014) · Journal of Neuroscience · doi:10.1523/jneurosci.1162-14.2014 · Cited by 155 · see citing works
Fragile X targeted pharmacotherapy: lessons learned and future directions
Erickson, C. A., Davenport, M. H., Schaefer, T. L., Wink, L. K., Pedapati, E. V., Sweeney, J. A., Fitzpatrick, S. E., Brown, W. T., Budimirovic, D. B., Hagerman, R. J., et al. (2017) · Journal of Neurodevelopmental Disorders · doi:10.1186/s11689-017-9186-9 · Cited by 153 · see citing works
Self-citationTranslation-relevant EEG phenotypes in a mouse model of Fragile X Syndrome.
Lovelace, J. W., Ethell, I. M., Binder, D. K., & Razak, K. A. (2018) · Neurobiology of Disease · doi:10.1016/j.nbd.2018.03.012 · Cited by 154 · see citing works
Sensory Processing Phenotypes in Fragile X Syndrome
Rais, M., Binder, D. K., Razak, K. A., & Ethell, I. M. (2018) · ASN NEURO · doi:10.1177/1759091418801092 · Cited by 128 · see citing works
Green, J., & Garg, S. (2018) · Journal of Child Psychology and Psychiatry · doi:10.1111/jcpp.12892 · Cited by 127 · see citing works
McDiarmid, T. A., Bernardos, A. C., & Rankin, C. H. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2017.05.028 · Cited by 119 · see citing works
Lovelace, J. W., Wen, T. H., Reinhard, S., Hsu, M. S., Sidhu, H., Ethell, I. M., Binder, D. K., & Razak, K. A. (2016) · Neurobiology of Disease · doi:10.1016/j.nbd.2016.02.002 · Cited by 115 · see citing works
Auditory Processing in Fragile X Syndrome
Rotschafer, S. E., & Razak, K. A. (2014) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2014.00019 · Cited by 102 · see citing works
Wilkinson, C. L., & Nelson, C. A. (2021) · Molecular Autism · doi:10.1186/s13229-021-00425-x · Cited by 101 · see citing works
Tomé, D., Barbosa, F., Nowak, K., & Teixeira, J. M. (2014) · Journal of Neural Transmission · doi:10.1007/s00702-014-1258-3 · Cited by 100 · see citing works
Fragile X Syndrome: From Molecular Aspect to Clinical Treatment
Protic, D. D., Aishworiya, R., Salcedo‐Arellano, M. J., Tang, S. J., Milisavljevic, J., Mitrovic, F., Hagerman, R. J., & Budimirovic, D. B. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23041935 · Cited by 89 · see citing works
Self-citationMultielectrode array analysis of EEG biomarkers in a mouse model of Fragile X Syndrome
Jonak, C. R., Lovelace, J. W., Ethell, I. M., Razak, K. A., & Binder, D. K. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.104794 · Cited by 87 · see citing works
Developmental studies in fragile X syndrome
Razak, K., Dominick, K., & Erickson, C. (2020) · Journal of Neurodevelopmental Disorders · doi:10.1186/s11689-020-09310-9 · Cited by 74 · see citing works
Lovelace, J. W., Rais, M., Palacios, A. R., Shuai, X. S., Bishay, S., Popa, O., Pirbhoy, P. S., Binder, D. K., Nelson, D. L., Ethell, I. M., et al. (2019) · Cerebral Cortex · doi:10.1093/cercor/bhz141 · Cited by 81 · see citing works
Neural Hyperexcitability in Autism Spectrum Disorders
Takarae, Y., & Sweeney, J. (2017) · Brain Sciences · doi:10.3390/brainsci7100129 · Cited by 82 · see citing works
Drug development for Autism Spectrum Disorder (ASD): Progress, challenges, and future directions
McCracken, J. T., Anagnostou, E. A., Arango, C., Dawson, G., Farchione, T. R., Mantua, V., McPartland, J. C., Murphy, D., Pandina, G., & Veenstra-VanderWeele, J. M. (2021) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2021.05.010 · Cited by 87 · see citing works
Developmental Changes in EEG Phenotypes in a Mouse Model of Fragile X Syndrome
Wen, T. H., Lovelace, J. W., Ethell, I. M., Binder, D. K., & Razak, K. A. (2018) · Neuroscience · doi:10.1016/j.neuroscience.2018.11.047 · Cited by 75 · see citing works
Transient ECM protease activity promotes synaptic plasticity
Magnowska, M., Górkiewicz, T., Beroun, A., Wawrzyniak, M., Rutkowska-Włodarczyk, I., Kaczmarek, L., & Włodarczyk, J. (2016) · Scientific Reports · doi:10.1038/srep27757 · Cited by 73 · see citing works
Brain-wide visual habituation networks in wild type and fmr1 zebrafish
Legorreta, E. M., Constantin, L., Piber, M., Favre‐Bulle, I. A., Taylor, M. A., Blevins, A. S., Giacomotto, J., Bassett, D. S., Vanwalleghem, G. C., & Scott, E. K. (2022) · Nature Communications · doi:10.1038/s41467-022-28299-4 · Cited by 71 · see citing works
Modulation of the GABAergic pathway for the treatment of fragile X syndrome
Hagerman, R. J., Lozano, R., & Hare, E. B. (2014) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s42919 · Cited by 66 · see citing works
Self-citationMechanisms underlying auditory processing deficits in Fragile X syndrome
McCullagh, E., Rotschafer, S., Auerbach, B. D., Klug, A., Kaczmarek, L. K., Cramer, K. S., Kulesza, R., Razak, K. A., Lovelace, J., Lu, Y., et al. (2020) · The FASEB Journal · doi:10.1096/fj.201902435r · Cited by 64 · see citing works
Pirbhoy, P. S., Rais, M., Lovelace, J. W., Woodard, W., Razak, K. A., Binder, D. K., & Ethell, I. M. (2020) · Journal of Neurochemistry · doi:10.1111/jnc.15037 · Cited by 62 · see citing works
van der Molen, M. J. W., Stam, C. J., & van der Molen, M. W. (2014) · PLoS ONE · doi:10.1371/journal.pone.0088451 · Cited by 57 · see citing works
Local cortical circuit correlates of altered EEG in the mouse model of Fragile X syndrome
Goswami, S., Cavalier, S., Sridhar, V., Huber, K. M., & Gibson, J. R. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.01.002 · Cited by 55 · see citing works
Díaz‐Caneja, C. M., State, M. W., Hagerman, R. J., Jacquemont, S., Marín, Ó., Bagni, C., Umbricht, D., Simonoff, E. A., Andres-Trelles, F., Kaale, A., et al. (2021) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2021.02.020 · Cited by 54 · see citing works
Self-citationNeural Correlates of Auditory Hypersensitivity in Fragile X Syndrome
Razak, K. A., Binder, D. K., & Ethell, I. M. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.720752 · Cited by 51 · see citing works
Treatment of the psychiatric problems associated with fragile X syndrome
Hagerman, R. J., & Polussa, J. (2015) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000000131 · Cited by 49 · see citing works
Self-citationDevitt, N. M., Gallagher, L., & Reilly, R. B. (2015) · Brain Sciences · doi:10.3390/brainsci5020092 · Cited by 57 · see citing works
Gamma power abnormalities in a Fmr1-targeted transgenic rat model of fragile X syndrome
Kozono, N., Okamura, A., Honda, S., Matsumoto, M., & Mihara, T. (2020) · Scientific Reports · doi:10.1038/s41598-020-75893-x · Cited by 47 · see citing works
Reusable Multielectrode Array Technique for Electroencephalography in Awake Freely Moving Mice
Jonak, C. R., Lovelace, J. W., Ethell, I. M., Razak, K. A., & Binder, D. K. (2018) · Frontiers in Integrative Neuroscience · doi:10.3389/fnint.2018.00053 · Cited by 42 · see citing works
Best Practices in Fragile X Syndrome Treatment Development
Erickson, C. A., Kaufmann, W. E., Budimirovic, D. B., Lachiewicz, A. M., Haas‐Givler, B., Miller, R. M., Weber, J. D., Abbeduto, L., Hessl, D. R., Hagerman, R. J., et al. (2018) · Brain Sciences · doi:10.3390/brainsci8120224 · Cited by 43 · see citing works
Self-citationEmerging pharmacologic treatment options for fragile X syndrome
Erickson, C. A., Schaefer, T. L., & Davenport, M. H. (2015) · The Application of Clinical Genetics · doi:10.2147/tacg.s35673 · Cited by 43 · see citing works
Carreño-Muñoz, M. I., Martins, F., Medrano, M., Aloisi, E., Pietropaolo, S., Dechaud, C., Subashi, E., Bony, G., Ginger, M. R., Moujahid, A., et al. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2017.149 · Cited by 40 · see citing works
The Search for an Effective Therapy to Treat Fragile X Syndrome: Dream or Reality?
Castagnola, S., Bardoni, B., & Maurin, T. (2017) · Frontiers in Synaptic Neuroscience · doi:10.3389/fnsyn.2017.00015 · Cited by 40 · see citing works
Hyperexcitability and impaired intracortical inhibition in patients with fragile-X syndrome
Morin‐Parent, F., Champigny, C. M., Lacroix, A., Corbin, F., & Lepage, J. (2019) · Translational Psychiatry · doi:10.1038/s41398-019-0650-z · Cited by 40 · see citing works
Repurposing available drugs for neurodevelopmental disorders: The fragile X experience
Tranfaglia, M. R., Thibodeaux, C., Mason, D. J., Brown, D., Roberts, I., Smith, R. J., Guilliams, T., & Cogram, P. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.05.004 · Cited by 39 · see citing works
Review of targeted treatments in fragile X syndrome
Ligsay, A., & Hagerman, R. J. (2016) · Intractable & Rare Diseases Research · doi:10.5582/irdr.2016.01045 · Cited by 37 · see citing works
Self-citationMinocycline Treatment Reverses Sound Evoked EEG Abnormalities in a Mouse Model of Fragile X Syndrome
Lovelace, J. W., Ethell, I. M., Binder, D. K., & Razak, K. A. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00771 · Cited by 36 · see citing works
EEG as a translational biomarker and outcome measure in fragile X syndrome
Kenny, A., Wright, D., & Stanfield, A. C. (2022) · Translational Psychiatry · doi:10.1038/s41398-022-01796-2 · Cited by 33 · see citing works
Pharmacotherapy for Fragile X Syndrome: Progress to Date
Davenport, M. H., Schaefer, T. L., Friedmann, K., Fitzpatrick, S. E., & Erickson, C. A. (2016) · Drugs · doi:10.1007/s40265-016-0542-y · Cited by 31 · see citing works
Developmental Emergence of Phenotypes in the Auditory Brainstem Nuclei ofFmr1Knockout Mice
Rotschafer, S. E., & Cramer, K. S. (2017) · eNeuro · doi:10.1523/eneuro.0264-17.2017 · Cited by 30 · see citing works
Toledo, M. A., Wen, T. H., Binder, D. K., Ethell, I. M., & Razak, K. A. (2019) · Behavioural Brain Research · doi:10.1016/j.bbr.2019.112068 · Cited by 31 · see citing works
Nguyen, A. O., Binder, D. K., Ethell, I. M., & Razak, K. A. (2020) · Journal of Neurophysiology · doi:10.1152/jn.00706.2019 · Cited by 28 · see citing works
Knoth, I. S., Lajnef, T., Rigoulot, S., Lacourse, K., Vannasing, P., Michaud, J. L., Jacquemont, S., Major, P., Jerbi, K., & Lippé, S. (2018) · Journal of Neurodevelopmental Disorders · doi:10.1186/s11689-018-9223-3 · Cited by 31 · see citing works
Kulinich, A., Reinhard, S. M., Rais, M., Lovelace, J., Scott, V., Binder, D., Razak, K., & Ethell, I. M. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.104622 · Cited by 27 · see citing works
Kokash, J., Alderson, E. M., Reinhard, S. M., Crawford, C. A., Binder, D. K., Ethell, I. M., & Razak, K. A. (2019) · Brain Research · doi:10.1016/j.brainres.2019.05.029 · Cited by 29 · see citing works
Quantitative EEG Analysis in Angelman Syndrome: Candidate Method for Assessing Therapeutics
Martinez, L. A., Born, H. A., Harris, S., Regnier‐Golanov, A., Grieco, J. C., Weeber, E. J., & Anderson, A. E. (2020) · Clinical EEG and Neuroscience · doi:10.1177/1550059420973095 · Cited by 25 · see citing works
Development of Neural Response to Novel Sounds in Fragile X Syndrome: Potential Biomarkers
Ethridge, L. E., Thaliath, A. P., Kraff, J., Nijhawan, K., & Berry‐Kravis, E. (2020) · American Journal on Intellectual and Developmental Disabilities · doi:10.1352/1944-7558-125.6.449 · Cited by 24 · see citing works
State‐of‐the‐art therapies for fragile X syndrome
Protic, D. D., & Hagerman, R. J. (2024) · Developmental Medicine & Child Neurology · doi:10.1111/dmcn.15885 · Cited by 24 · see citing works
Self-citationSalazar, I. L., Caldeira, M. V., Curcio, M., & Duarte, C. B. (2015) · Neurochemical Research · doi:10.1007/s11064-015-1752-5 · Cited by 25 · see citing works
Functional consequences of postnatal interventions in a mouse model of Fragile X syndrome
Rais, M., Lovelace, J. W., Shuai, X. S., Woodard, W., Bishay, S., Estrada, L., Sharma, A. R., Nguy, A. K., Kulinich, A. O., Pirbhoy, P. S., et al. (2021) · Neurobiology of Disease · doi:10.1016/j.nbd.2021.105577 · Cited by 22 · see citing works
Baclofen-associated neurophysiologic target engagement across species in fragile X syndrome
Jonak, C. R., Pedapati, E. V., Schmitt, L., Assad, S. A., Sandhu, M. S., DeStefano, L. A., Ethridge, L. E., Razak, K. A., Sweeney, J. A., Binder, D. K., et al. (2022) · Journal of Neurodevelopmental Disorders · doi:10.1186/s11689-022-09455-9 · Cited by 23 · see citing works
EEG Signal Complexity Is Reduced During Resting-State in Fragile X Syndrome
Proteau-Lemieux, M., Knoth, I. S., Agbogba, K., Côté, V., Biag, H. M. B., Thurman, A. J., Martin, C.-O., Bélanger, A.-M., Rosenfelt, C. S., Tassone, F., et al. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.716707 · Cited by 22 · see citing works
Self-citationJonak, C., Assad, S. A., Sandhu, M., Garcia, T. A., Rumschlag, J., Razak, K., & Binder, D. (2024) · Neurobiology of Disease · doi:10.1016/j.nbd.2024.106496 · Cited by 19 · see citing works
Genetics, molecular control and clinical relevance of habituation learning
Blok, L. E. R., Boon, M., van Reijmersdal, B., Höffler, K. D., Fencková, M., & Schenck, A. (2022) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2022.104883 · Cited by 21 · see citing works
Jonak, C. R., Sandhu, M. S., Assad, S. A., Barbosa, J. A., Makhija, M. T., & Binder, D. K. (2021) · Neurotherapeutics · doi:10.1007/s13311-021-01005-w · Cited by 18 · see citing works
Champigny, C., Morin-Parent, F., Bellehumeur-Lefebvre, L., Çaku, A., Lepage, J.-F., & Corbin, F. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.762967 · Cited by 16 · see citing works
New Therapeutic Options for Fragile X Syndrome
Jalnapurkar, I. R., Cochran, D., & Frazier, J. A. (2019) · Current Treatment Options in Neurology · doi:10.1007/s11940-019-0551-8 · Cited by 15 · see citing works
Targeted treatments in fragile X syndrome
Hare, E. B., Hagerman, R. J., & Lozano, R. (2014) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2014.903795 · Cited by 14 · see citing works
Self-citationFragile X Syndrome: Lessons Learned and What New Treatment Avenues Are on the Horizon
Hagerman, R. J., & Hagerman, P. J. (2021) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-052120-090147 · Cited by 12 · see citing works
Self-citationElectrophysiological Biomarkers in Genetic Epilepsies
Armstrong, C., & Marsh, E. D. (2021) · Neurotherapeutics · doi:10.1007/s13311-021-01132-4 · Cited by 12 · see citing works
Targeted therapy of cognitive deficits in fragile X syndrome
Puścian, A., Winiarski, M. J., Borowska, J., Łęski, S., Górkiewicz, T., Chaturvedi, M., Nowicka, K., Wołyniak, M., Chmielewska, J. J., Nikolaev, T., et al. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01527-5 · Cited by 11 · see citing works
Clinical significance of matrix metalloproteinase-9 in Fragile X Syndrome
Laroui, A., Galarneau, L., Abolghasemi, A., Benachenhou, S., Plantefève, R., Bouchouirab, F. Z., Lepage, J., Corbin, F., & Çaku, A. (2022) · Scientific Reports · doi:10.1038/s41598-022-19476-y · Cited by 10 · see citing works
An, W. W., Nelson, C. A., & Wilkinson, C. L. (2022) · Frontiers in Integrative Neuroscience · doi:10.3389/fnint.2022.987184 · Cited by 10 · see citing works
Matusiak, M., Oziębło, D., Ołdak, M., Rejmak, E., Kaczmarek, L., Skarzynski, P. H., & Skarżyńśki, H. (2022) · Molecular Neurobiology · doi:10.1007/s12035-022-02732-7 · Cited by 9 · see citing works
Erickson, C. A., Shaffer, R. C., Will, M., Schmitt, L., Horn, P. S., Hirst, K., Pedapati, E. V., Ober, N., Tumuluru, R. V., Handen, B. L., et al. (2023) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-023-06132-1 · Cited by 8 · see citing works
Studying child development in genetic models of ASD
Garg, S., & Green, J. (2018) · Progress in brain research · doi:10.1016/bs.pbr.2018.09.009 · Cited by 8 · see citing works
Hyper-extralemniscal model of Fragile X syndrome
Miyakoshi, M., Kim, H., Stefano, L. A. D., Schmitt, L., Norris, J. E., Ethridge, L. E., Erickson, C. A., & Pedapati, E. V. (2025) · Cerebral Cortex · doi:10.1093/cercor/bhaf141 · Cited by 6 · see citing works
Auger, E., Berry-Kravis, E. M., & Ethridge, L. E. (2022) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2022.109501 · Cited by 6 · see citing works
Astrocytic GABA controls fidelity of temporal cortical processing in Fragile X Syndrome
Wagner, V. A., Thapa, R., Norman, A. O., Varallo, A., Wimberly, J., Rais, M., Gerasymchuk, D., Piepponen, P. T., Razak, K. A., Castrén, M. L., et al. (2025) · Neurobiology of Disease · doi:10.1016/j.nbd.2025.107233 · Cited by 7 · see citing works
Morin‐Parent, F., Champigny, C. M., Cote, S. R., Mohamad, T., Hasani, S. A., Çaku, A., Corbin, F., & Lepage, J. (2024) · Autism Research · doi:10.1002/aur.3222 · Cited by 5 · see citing works
McKinney, W. S., Schmitt, L., Stefano, L. A. D., Ethridge, L. E., Norris, J. E., Horn, P. S., Dauterman, S., Rosselot, H., Pedapati, E. V., Reisinger, D. L., et al. (2024) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2024.0103 · Cited by 5 · see citing works
Fragile X-Associated Disorders
Lozano, R., Hare, E. B., & Hagerman, R. J. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-410529-4.00017-6 · Cited by 5 · see citing works
Self-citationOverview of Targeted Double-Blind, Placebo-Controlled Clinical Trials in Fragile X Syndrome
Ligsay, A., Hagerman, R. J., & Berry‐Kravis, E. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804461-2.00019-6 · Cited by 4 · see citing works
Self-citationHarkins, C. M., Dominick, K. C., Wink, L. K., Pedapati, E. V., Shaffer, R. C., Fitzpatrick, S. E., Davenport, M. H., Sweeney, J. A., & Erickson, C. A. (2017) · Pharmaceutical Medicine · doi:10.1007/s40290-017-0199-1 · Cited by 4 · see citing works
Pharmacological Treatments for Fragile X Syndrome Based on Synaptic Dysfunction
Telias, M. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666191102165206 · Cited by 4 · see citing works
Fragile X-Associated Disorders
Summers, S. M., & Hagerman, R. J. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-398270-4.00008-2 · Cited by 4 · see citing works
Self-citationStanfield, A. C., & McKechanie, A. G. (2025) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2025.2510408 · Cited by 3 · see citing works
Drug Discovery for Targeted Pharmacotherapy of Fragile X Syndrome
Scharf, S., Gasparini, F., Spooren, W., & Lindemann, L. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804461-2.00018-4 · Cited by 1 · see citing works
Rais (2022) · doi:10.1101/2022.02.08.479618 · Cited by 2 · see citing works
Matrix Metalloproteinases in Fragile X Syndrome
Ethell, D. W., & Sidhu, H. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804461-2.00015-9 · Cited by 2 · see citing works
Goel, A., Razak, K. A., Chubykin, A. A., & Antoine, M. W. (2025) · Journal of Neurodevelopmental Disorders · doi:10.1186/s11689-025-09634-4 · Cited by 1 · see citing works
Legorreta, E. M. (2020) · The University of Queensland · doi:10.14264/uql.2020.647
Baclofen-Associated Neurophysiologic Target Engagement Across Species in Fragile X SyndromePreprint
Jonak, C. R., Pedapati, E. V., Schmitt, L., Assad, S. A., Sandhu, M. S., DeStefano, L. A., Ethridge, L. E., Razak, K. A., Sweeney, J. A., Binder, D. K., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-970688/v1
Síndrome X frágil y otras patologías asociadas al gen FMR1
Juárez, J. C. C., de León, M. J. Z., Díaz, D. J. S., Alvarado, C. G. B., García, D. A. S., & Arévalo, G. S. (2021) · Revista Med · doi:10.18359/rmed.5262
An, W. W., Nelson, C. A., & Wilkinson, C. L. (2022) · medRxiv · doi:10.1101/2022.07.05.22277114
Steenbergen, A. V., Minhas, A., Lin, T. R., Kaur, M., & Bolduc, F. V. (2023) · Research Square · doi:10.21203/rs.3.rs-3439158/v1
Chojnacka, M., Skupien, A., & Dziembowska, M. (2025) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2025.1604262
Associations Between Altered Auditory EEG Markers and Clinical Impairments in Fragile X Syndrome
Proteau-Lemieux, M., Knoth, I. S., Davoudi, S., Martin, C.-O., Bélanger, A.-M., Fontaine, V. K., Biag, H. M. B., Abbeduto, L., Jacquemont, S., Hessl, D. R., et al. (2025) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-025-07076-4 · Cited by 1 · see citing works
Self-citationKassir, M. H., Lovelace, J. W., Binder, D. K., Ethell, I. M., & Razak, K. A. (2025) · ASN NEURO · doi:10.1080/17590914.2025.2564628
- Authors
- Schneider, A., Leigh, M. J., Adams, P., Nanakul, R., Chechi, T., Olichney, J., Hagerman, R., & Hessl, D.
- Affiliations
- University of California Davis Medical Center (US)
- University of Washington (US)
- Venue
- Journal of Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2013-08-27
- Volume
- 27
- Issue
- 10
- Pages
- 956-963
- ISSN
- 0269-8811 (ISSN-L)
- 1461-7285
- PMC
- PMC4962861
- OpenAlex
- W2006050076
- Cited by
- 108
- References
- 29
- Citations by year
- 2026: 3 · 2025: 7 · 2024: 4 · 2023: 2 · 2022: 15 · 2021: 12 · 2020: 10 · 2019: 11 · 2018: 10 · 2017: 13 · 2016: 7 · 2015: 6 · 2014: 8
- FWCI
- 4.64
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Fragile X Foundation
- Centers for Disease Control and Prevention (U50DD000596)
- National Institute on Aging (NIARL1AG032115, RL1AG032115)
- National Center for Research Resources (UL1RR024141, UL1RR024146, KL2RR024141)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetics and Neurodevelopmental Disorders
- Life Sciences › Neuroscience › Cognitive Neuroscience › Autism Spectrum Disorder Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- fragile X syndrome, minocycline, event-related potentials, auditory oddball paradigm, current source density, N1 and P2 components, cognitive biomarkers, treatment response monitoring, children
- MeSH terms
- Anti-Bacterial Agents, Child, Double-Blind Method, Evoked Potentials, Auditory, Female, Fragile X Syndrome, Habituation, Psychophysiologic, Humans, Male, Minocycline, Cross-Over Studies, Biomarkers, Pharmacological
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
